Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: Results from the SMART study 2009-2010

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 1, 2012, Pages 62-67

  Hoban, Daryl J ^a   Lascols, Christine ^a   Nicolle, Lindsay E ^b   Badal, Robert ^a   Bouchillon, Sam ^a   Hackel, Meredith ^a   Hawser, Stephen ^c  

^a International Health Management Associates   (United States)

^b HEALTH SCIENCES CENTRE   (Canada)

^c International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

Enterobacteriaceae; Extended; Lactamase; Spectrum beta; Urinary tract infection

Indexed keywords

AMIKACIN; BETA LACTAMASE CTX M; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTAZIDIME PLUS CLAVULANIC ACID; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; UNCLASSIFIED DRUG;

AMPC GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BLA CTX M GENE; BLA KPC GENE; BLA TEM GENE; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EUROPE; HOSPITAL PATIENT; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; EUROPE; FEMALE; GENOTYPE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; URINARY TRACT INFECTIONS;

EID: 84865283710     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.05.024     Document Type: Article

References (24)

1. Alhambra A., Cuadros J.A., Cacho J., Gómez-Garcés J.L., Alós J.I. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004, 53:1090-1094.
2. Bader M.S., Hawboldt J., Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2010, 122:7-15.
3. Bogaerts P., Hujer A.M., Nass T., Rezende de Castro R., Endimiani A., Nordmann P., et al. Multicenter evaluation of a new DNA microarray for rapid detection of clinically relevant bla genes from beta-lactam-resistant Gram-negative bacteria. Antimicrob Agents Chemother 2011, 55:4457-4460.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 21st informational supplement (M100-S22) 2012, CLSI, Wayne, PA.
5. Gordon K.A., Jones R.N. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe, Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2003, 45:295-301.
6. Hawser S.P., BouchillonSK Hoban D.J., Badal R.E., Cantón R., Baquero F. Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae and extended-spectrum ß-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010, 54:3043-3046.
7. Hoban D.J., Bouchillon S., Hawser S.P., Badal R.E., LaBombardi V.J., DiPersio J. Susceptibility of Gram-negative pathogens isolated from complicated intra-abdominal infections in the United States 2007-2008: results of the SMART study. Antimicrob Agents Chemother 2010, 54:3031-3034.
8. Hoban D.J., BouchillonSK Hawser S.P., Badal R.E. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagn Microbiol Infect Dis 2010, 66:78-86.
9. Hoban D.J., Nicolle L.E., Hawser S., Bouchillon S., Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011, 70:507-511.
10. Hsueh P.-R., Hoban D.J., Carmeli Y., Chen S.-Y., Desikan S., Alenjandria M., et al. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect 2011, 63:114-123.
11. Lascols C., Hackel M., Marshall S.H., Hujer A.M., Bouchillon S., Badal R., et al. Increasing prevalence and dissemination of NDM-1 metallo-beta-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother 2011, 66:1992-1997.
12. Mathai D., Jones R.N., Pfaller M.A. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis 2001, 40:129-136. The SENTRY Participant Group North America.
13. Meier S., Weber R., Zbinden R., Ruef C., Hasse B. Extended-spectrum ß-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 2011, 39:333-340.
14. Mena A., Plasencia V., Garcia L., Hidalgo G.O., Ayestaran J.I., Alberti S., et al. Characterization of a large outbreak of CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbial 2006, 44:2831-2837.
15. Mulvey M.R., Bryce E., Boyd D., Ofner-Agostini M., Christianson S., Simor A.E., et al. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Chemother 2004, 48:1204-1214.
16. Nuesch-Inderbinen M.T., Hachler H., Kayser F.H. Detection of genes coding for extended-spectrum SHV beta-lactamases in clinical isolates by a molecular genetic method, and comparison with the E test. Eur J Clin Microbiol Infect Dis 1996, 15:398-402.
17. Paterson D.L. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Med 2006, 119:S20-S28.
18. Perez F., Endimiani A., Hujer K.M., Bonomo R.A. The continuing challenge of ESBLs. Curr Opin Pharmacol 2007, 7:459-469.
19. Speldooren V., Heym B., Labia R., Nicolas-Chanoine M.H. Discriminatory detection of inhibitor-resistant beta-lactamases in Escherichia coli by single-strand conformation polymorphism-PCR. Antimicrob Agents Chemother 1998, 42:879-884.
20. Wagenlehner F.M.E., Niemetz A.H., Weidner W., Naber K.G. Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2005. Int J Antimicrob Agents 2008, 31S:S25-S34.
21. Wagenlehner F.M.E., Cek M., Naber K.G., Kiyota H., Bjerklund-Johansen T.E. Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol 2012, 30:59-67.
22. Woodford N., Fagan E.J., Ellington M.J. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases. J Antimcirob Chemother 2006, 57:154-155.
23. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.W., Steward C.D., et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001, 45:1151-1161.
24. Zhanel G.G., DeCorby M., Adam H., Mulvey M.R., McCracken M., Lagacé-Wiens P., et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother 2010, 54:4684-4693.